ALSO NOTED: Washington biotech investing in growth; Merck CEO: 'I can't blame the media'; NeuroMetrix's CEO resigns; and much m

> Despite the economic slowdown, Washington state biotechs are investing hundreds of millions of dollars in new facilities. Report

> Merck CEO Dick Clark worried publicly about the media at a Morgan Stanley conference yesterday. In response to a question about the negative bent to Merck coverage these days, Clark said Merck and pharma as a whole both need to "do a better job...I don't think we're aggressive enough in getting our stories out there. Merck Report

> Chutes & Ladders: NeuroMetrix's CEO Gary L. Gregory is leaving the company to pursue new professional opportunities. Release

> Researchers for Sweden's Independent Pharmaceutica are launching a mid-stage study of a new nicotine vaccine designed to help people give up smoking. Vaccine report

> A team of researchers at Emory University and the Oklahoma Medical Research Foundation has found a way to radically upend the way new vaccines are developed to fight a pandemic. Report

> A large group of American parents are having a tough time keeping up with their kids' vaccination schedules. Report

> Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a boxed warning about tuberculosis and other life-threatening illness; the label states that patients using the drug have contracted infections that led to hospitalization and death. Enbrel report

> Next week, Rep. Bart Stupak will preside over testimony from Pfizer, Merck, Schering-Plough, and Johnson & Johnson at the Subcommittee on Oversight and Investigations' hearing on direct-to-consumer ads. Report

And Finally... A federal advisory panel is calling for closer regulation of companies that provide genetic tests. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."